Skip to search formSkip to main contentSkip to account menu

MDL 19,205

Known as: MDL 19205, MDL-19,205, MDL-19205 
National Institutes of Health

Related topics

Related topics

1 relation

Broader (1)

piroximone

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2005
2005
Comparative study of MDL 17043 and MDL 19205, new positive inotropic agents, by use of isolated, blood-perfused dog-heart preparations
SummaryThe cardiac and coronary vasodilator effects of MDL 17043 and MDL 19205 were compared in isolated, blood-perfused… 
1988
1988
Acute hemodynamic effects of MDL 19205 on conscious dogs with mitral regurgitation
SummaryTo assess the effects of MDL 19205, a combined inotropic-vasodilating agent, or an inodilator, on the left ventricle with… 
1987
1987
Effects of Long‐Term Therapy with Oral Piroximone on Resting Hemodynamics, Peak Aerobic Capacity, and the Anaerobic Threshold in Patients with Heart Failure
Summary Piroximone (MDL 19205), a new imidazole derivative with positive inotropic and vasodilating properties, was administered… 
1987
1987
Acute Hemodynamic Effects of MDL 19205 in Mild Congestive Heart Failure
MDL 19205 4-ethyl-1-,3-dihydro-5-(4-pyridinylcarbonyl)-2H-imidazol-2-one, a new cardioactive agent, has been shown to increase… 
1986
1986
Persistent hemodynamic effects without long-term clinical benefits in response to oral piroximone (MDL 19,205) in patients with congestive heart failure.
Piroximone (MDL 19,205), a new phosphodiesterase inhibitor with positive inotropic and vasodilating properties, was administered… 
1986
1986
Acute Hemodynamic Effects of Piroximone (MDL 19,205) in Patients with Moderate Congestive Heart Failure: Comparison with Sodium Nitroprusside
Summary: Piroximone (MDL 19,205), a new imidazolone derivative, was given intravenously to 14 patients with congestive heart… 
1986
1986
Effects of MDL 19205 (Piroximone), A New Cardiotonic Agent, on Electrophysiological, Mechanical, and Intracellular Ionic Characteristics of Sheep Cardiac Tissues
Summary: This study was undertaken to characterize the cardiac electrophysiological and mechanical effects of MDL 19205, a new… 
1984
1984
In Vitro and In Vivo Assessment of the Cardiovascular Effects of the Cardiotonic Drug MDL 19205
Various in vitro and in vivo techniques were used to evaluate the cardiovascular actions of MDL 19205, a new cardiotonic agent… 
1984
1984
Studies on the Mechanism of the Cardiotonic Activity of MDL 19205: Effects on Several Biochemical Systems
MDL 19205, 4-ethyl-l, 3-dihydro-5-(4-pyri-dinyl-carbonyl)-2 H-imidazol-2-one, is a new drug with cardiotonic properties. Its… 
1983
1983
Method of analysis of the new cardiotonic agent, MDL 19,205, in plasma and urine and its application in a dog pharmacokinetic study.
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)